The ongoing Phase 1 clinical study (NCT02546921, www.clinicaltrials.gov) of MOv18, a first-in-class therapeutic IgE antibody for ovarian cancer therapy, represents a substantial advance for the field, and it underlines the importance of further exploration of the safety profile and clinical applicability of IgE therapeutics against different tumor targets. This evidence concerns the gene IGHE and ovarian carcinoma.